Overview

Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the benefit of adding docetaxel-5 fluorouracile (D-5FU) regimen after pre-operative epirubicin-cyclophosphamide (EC) and loco-regional treatment in inflammatory breast cancer (IBC).
Phase:
Phase 3
Details
Lead Sponsor:
UNICANCER
Treatments:
Cyclophosphamide
Docetaxel
Epirubicin